Investigators Seek Clues to Resistance to Melanoma Drug
Friday, January 27th, 2012Investigators at Vanderbilt-Ingram Cancer Center and several other centers may be one step closer to finding out why some melanoma patients relapse after treatment with a promising new drug. Approximately half of all patients with the most deadly form of skin cancer have a mutation in the BRAF gene in their tumors that drives the [...]
Subscribe 
Join Us